Skip to main content

BioAtla, Inc. (BCAB)

NASDAQ: BCAB · IEX Real-Time Price · USD
34.75
+0.20 (0.58%)
After-hours:Sep 17, 2021 6:36 PM EDT
34.55
-2.12 (-5.78%)
At close: Sep 17, 4:00 PM
Market Cap1.22B
Revenue (ttm)400,000
Net Income (ttm)n/a
Shares Out32.32M
EPS (ttm)-2.02
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,310,762
Open36.56
Previous Close36.67
Day's Range34.51 - 37.10
52-Week Range27.15 - 76.63
Betan/a
AnalystsBuy
Price Target76.25 (+120.7%)
Est. Earnings DateNov 12, 2021

About BCAB

BioAtla, Inc., a biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of various cancers. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and other tumor types. It also develops BA3021, a CAB ADC for NSCLC and Melanoma; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, h...

IndustryBiotechnology
IPO DateDec 16, 2020
Employees36
Stock ExchangeNASDAQ
Ticker SymbolBCAB
Full Company Profile

Financial Performance

In 2020, BioAtla's revenue was $429,000, a decrease of -91.75% compared to the previous year's $5.20 million. Losses were -$35.85 million, 20.3% more than in 2019.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for BioAtla stock is "Buy." The 12-month stock price forecast is 76.25, which is an increase of 120.69% from the latest price.

Price Target
$76.25
(120.69% upside)
Analyst Consensus: Buy

News

BioAtla Announces Second Quarter 2021 Financial Results And Provides Clinical Update

SAN DIEGO, Aug. 13, 2021 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeuti...

1 month ago - PRNewsWire

BioAtla Announces First Quarter 2021 Financial Results And Provides Business Update

SAN DIEGO, May 12, 2021 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutic...

4 months ago - PRNewsWire

BioAtla to Present at 39th Annual J.P. Morgan Virtual Healthcare Conference

SAN DIEGO, Jan. 8, 2021 /PRNewswire/ -- BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announ...

8 months ago - PRNewsWire

Notable Insider Buys In The Week Of Christmas: Foot Locker, GameStop, NetApp And More

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from it. So insider buying can b...

8 months ago - Benzinga

BioAtla Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additi...

SAN DIEGO, Dec. 18, 2020 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a clinical-stage biopharmaceutical company developing a novel class of highly specific and selective antibody-based therapeutics fo...

8 months ago - PRNewsWire

BioAtla Announces Pricing of Initial Public Offering

SAN DIEGO, Dec. 15, 2020 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a clinical-stage biopharmaceutical company developing a novel class of highly specific and selective antibody-based therapeutics fo...

9 months ago - PRNewsWire

IPO Preview: BioAtla Begins $100 Million IPO Effort

San Diego, California-based BioAtla was founded to develop conditionally active biologics that 'exploit characteristic pH differences between the tumor microenvironment and healthy tissue.'

9 months ago - TheStreet

Solid tumor biotech BioAtla files for a $100 million IPO

BioAtla, a Phase 2 biotech developing antibody therapies for solid tumor cancers, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

10 months ago - NASDAQ

BioAtla IPO Registration Document (S-1)

BioAtla, Inc. has filed to go public with an IPO on the New York Stock Exchange (NYSE).

10 months ago - SEC